An imaging target TGF-β1 for hepatocellular carcinoma in mice.
It has been reported that the positive detection rate of Fluorine-18-fluorodeoxyglucose (18F-FDG) metabolism in positron emission tomography (PET) imaging, for the diagnosis of hepatocellular carcinoma (HCC) is only about 50%. In particular,18F-FDG PET imaging is prone to false negative findings in HCC. Transforming growth factor-beta1 (TGF-β1) shows over expression rates in early HCC liver tissue growth and promotes tumor invasion and metastases. Our aim was to use In this study, we used the feasibility of iodine-125 (125I)-labeled TGF-β1 antibody as a nuclear medicine imaging target in HCC.


METHODS
The TGF-β1 antibody was obtained from Bioss Inc. The Huh-7 cell line (Liver Cancer Institute, Zhongshan Hospital, Fudan University) is a HCC cell line with high metastatic potential. Each mouse was subcutaneously injected with 5×106/0.1mL Huh-7 cells in the right upper flank region for the establishment of a subcutaneous xenograft model. The Iodogen method was used to label TGF-β1 antibody with125I. In this experiment, 100μL of125I- TGF-β1 antibody solution, which contained approximately 18,5MBq of125I-liraglutide, was injected into the tail veins of each of three nude mice with Huh-7 HCC. Micro SPET/CT imaging was performed for each mouse using a nano SPET/CT.


RESULTS
The average percentage of injected dose per gram of tissue (ID%) was 1,3% and 2,4%. The tumor was strongly positive for TGF-β1.


CONCLUSIONS
This pilot study provides an experimental basis for further exploration of the feasibility of TGF-β1 receptor as a target in HCC imaging and in other cancers.
Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. shi.hongcheng@zs-hospital.sh.cn.
Yiqiu
Y
Zhang
Beilei
B
Li
Xiao
X
Li
Hui
H
Tan
Dengfeng
D
Cheng
Hongcheng
H
Shi
D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics*; D014408:Biomarkers, Tumor / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging* / Q000378:metabolism*; D045744:Cell Line, Tumor; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics*; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism; D008297:Male; D008657:Metabolic Clearance Rate; D051379:Mice; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D025202:Molecular Diagnostic Techniques / Q000379:methods*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D000072098:Single Photon Emission Computed Tomography Computed Tomography / Q000379:methods; D014018:Tissue Distribution; D053773:Transforming Growth Factor beta1 / Q000378:metabolism*
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D053773:Transforming Growth Factor beta1